ClinicalTrials.gg
CompletedNCT05213624Updated Jan 12, 2026Results posted

A Study to Test BI 764198 in People With a Type of Kidney Disease Called Focal Segmental Glomerulosclerosis

A Phase 2 interventional study of BI 764198 and Placebo in Kidney Disease, Chronic, sponsored by Boehringer Ingelheim. Completed at 54 sites in 10 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-01-12.

Sponsored by Boehringer Ingelheim · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
67
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 13 studies in Renal Insufficiency, Chronic by Boehringer Ingelheim — none open to participants now, 4 under way, 2 of them phase 3. Renal Insufficiency, Chronic · Boehringer Ingelheim.

Enrollment
8th of 10
67 · median 242
Started
2022
with 1 other
Phase 2
5 of 13
none open now
Registered
7th of 13
by date

Among the 13 studies in Renal Insufficiency, Chronic by Boehringer Ingelheim, this one is the 8th largest by enrollment of the 10 interventional ones that give a count, is one of 2 that started in 2022, is one of 5 in phase 2, and was the 7th registered.

Renal Insufficiency, Chronic

3,096 studies on the registry are indexed under Renal Insufficiency, Chronic; 701 are open to participants now.

Browse Renal Insufficiency, Chronic studies →

Open to participants now

None of the 13 studies in Renal Insufficiency, Chronic by Boehringer Ingelheim is open now. The open studies under Renal Insufficiency, Chronic, anywhere →

Who these studies take

Of the 435 Renal Insufficiency, Chronic studies recruiting now, 244 (56%) set no upper age limit and 111 (26%) stop at 75 or younger; 45 take children under 18; 80 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 13 studies in Renal Insufficiency, Chronic by Boehringer Ingelheim as a file.
02

Study summary

This study is open to adults with a type of kidney disease called focal segmental glomerulosclerosis (FSGS). The purpose of this study is to find out whether a medicine called BI 764198 improves the health of the kidneys in people with FSGS. Three different doses of BI 764198 are tested in this study.

Participants are put into 4 groups randomly, which means by chance. Three of the groups receive different doses of BI 764198 and one group receives placebo. Participants are in the study for about 4 months. For about 3 months, they take BI 764198 or placebo as capsules once a day.

Placebo capsules look like BI 764198 capsules but do not contain any medicine. Participants visit the study site about 10 times. You can participate in this study from your home. In this case a research nurse will visit you for the study visits.

Kidney health is assessed based on the analysis of urine samples, which participants collect at home. At the end of the study, the results are compared between the different groups. During the study, the doctors also regularly check the general health of the participants.

03

Conditions studied

  • Kidney Disease, Chronic
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male and female patients 18 years to 75 years (both inclusive) of age on the day of signing .
  • Patients diagnosed with proven primary Focal Segmental Glomerulosclerosis (FSGS) or documented Transient Receptor Potential Cation subfamily C Member 6 (TRPC6) gene mutation causing FSGS prior to screening visit.
  • Urine Protein-Creatinine Ratio (UPCR) ≥ 1000 mg/g based on first morning void urine sample during screening.
  • Patients treated with must be on a stable dose for at least 4 weeks prior to screening visit with no plan to change the dose until end of trial treatment.
  • Patients treated with Angiotensin Converting Enzyme (ACE) inhibitors, Angiotensin II Receptor Blockers (ARBs), finerenone, aldosterone inhibitors, or Sodium-Glucose Cotransporter-2 (SGLT2) inhibitors should be on a stable dose for at least 4 weeks prior to screening visit with no plan to change the dose until end of trial treatment.
  • (BMI) of ≤ 40 kg/m² at screening visit.
  • Women of (WOCBP) must be willing and able to use highly effective methods of per ICH M3 (R2) that result in a low failure rate of less than 1% per year when used consistently and correctly. A list of contraception methods meeting these criteria is provided in the informed consent form (ICF) and in the study protocol.

Further inclusion criteria apply.

Exclusion criteria

Exclusion criteria:

  • Known monogenic (with the exception of TRPC6 gene mutations) or clinical or histologic evidence of secondary FSGS.
  • Documented Alport syndrome, Nail Patella syndrome, diabetic nephropathy, Immunoglobulin A (IgA)-nephropathy, lupus nephritis, or monoclonal gammopathy (e.g., multiple myeloma).
  • Concomitant use of calcineurin inhibitors.
  • Concomitant treatment with cytotoxic agents (cyclophosphamide, chlorambucil), or CD20 monoclonal antibody, e.g., rituximab, within 5 half-lives before screening visit. Note: use of other therapies considered as standard of care may be allowed as long as the patient remains on stable dose throughout the study.
  • Estimated (eGFR) \< 30 mL/min/1.73 m² at screening visit.
  • Time between start of the Q-wave and end of the T-wave in an interval corrected for heart rate () intervals (QT interval corrected for heart rate using the method of Fridericia - QTcF) greater than 450 ms in males or greater than 470 ms in females, or any other electrocardiogram (ECG) findings (at the investigator's discretion) at screening visit.
  • Detection of graded cataract by Lens Opacities Classification System III (LOCS III) higher than NC1/NO1, C0, P0 in the slit lamp eye examination at screening visit. Planned cataract surgery during participation in the study. Patients with cataract who have undergone lens replacement are not excluded.
  • Women who are pregnant, nursing, or who plan to become pregnant while in the study.

Further exclusion criteria apply.

Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
67 participants (actual)

Study arms

  • Experimental
    BI 764198 20 mg

    Patients with primary focal segmental glomerulosclerosis (FSGS) or patients with monogenic FSGS as a result of TRPC6 mutations took daily one single capsule of 20 milligrams (mg) of BI 764198 orally for 12 weeks.

    Drug: BI 764198

  • Experimental
    BI 764198 40 mg

    Patients with primary focal segmental glomerulosclerosis (FSGS) or patients with monogenic FSGS as a result of TRPC6 mutations took daily one single capsule of 40 milligrams (mg) of BI 764198 orally for 12 weeks.

    Drug: BI 764198

  • Experimental
    BI 764198 80 mg

    Patients with primary focal segmental glomerulosclerosis (FSGS) or patients with monogenic FSGS as a result of TRPC6 mutations took daily one single capsule of 80 milligrams (mg) of BI 764198 orally for 12 weeks.

    Drug: BI 764198

  • Placebo comparator
    Placebo

    Patients with primary focal segmental glomerulosclerosis (FSGS) or patients with monogenic FSGS as a result of TRPC6 mutations took daily one single capsule of placebo-matching BI 764198 orally for 12 weeks.

    Drug: Placebo

Interventions

  • One single capsule of 20 milligrams (mg), 40 mg, or 80 mg of BI 764198 orally, once a day.

  • DrugPlacebo

    One single capsule of placebo matching BI 764198 orally, once a day.

06

What researchers measure

Primary outcomes

  1. Achievement of at Least 25% Reduction in 24-hour Urine Protein Creatinine Ratio (UPCR) Relative to Baseline at Week 12

    Predicted probability of patients as a percentage - predicted percentage of patients - achieving at least 25% reduction in 24-hour urine protein creatinine ratio (UPCR) relative to baseline at Week 12 (responders) is reported. Baseline was the average of two 24-hour urine samples collected before Visit 2 (Week 0). Patients who either missed their Week 12, 24-hour UPCR assessment or their Week 12, 24-hour UPCR assessment, occurred later than 5 days after the last dose (Residual Effect Period), were considered as non-responders. The predicted probability of response was calculated using a logistic regression utilizing corticosteroid use at randomization and baseline 24-hr UPCR as covariates and is presented as a percentage.

    Time frame: At baseline and Week 12.

  2. Relative Change From Baseline at Week 12 of 24-hour Urine Protein Creatinine Ratio (UPCR)

    Relative change from baseline at Week 12 in 24-hour urine protein creatinine ratio (UPCR), is reported. Baseline was the average of two 24-hour urine samples collected before Visit 2 (Week 0). An analysis of covariance (ANCOVA) model was used to estimate the relative change in UPCR from baseline to Week 12 with corticosteroid use at randomization and baseline 24-hr UPCR as covariates.

    Time frame: At baseline and at Week 12.

Secondary outcomes

  1. Change in 24-hour Urine Protein Creatinine Ratio (UPCR) Relative to Visit 3 at Week 12

    Median change in 24-hour urine protein creatinine ratio (UPCR) relative to Visit 3 (Week 1) at Week 12, is calculated by subtracting the 24-hour UPCR, \[Week 12\] - \[Week 1\] values per patient, then by calculating the median of these changes, per treatment group.

    Time frame: At Week 1 and Week 12.

  2. Change in 24-hour Urine Protein Creatinine Ratio (UPCR) Relative to Baseline at Week 13

    Median change in 24-hour urine protein creatinine ratio (UPCR) relative to baseline at Week 13, is calculated by subtracting the 24-hour UPCR, \[Week 13\] - \[baseline\] values per patient,then by calculating the median of these changes, per treatment group. Baseline was the average of two, 24-hour urine samples collected before Visit 2 (Week 0).

    Time frame: At baseline and at Week 13.

  3. Change in 24-hour Urinary Protein Excretion Relative to Baseline at Week 12

    Median change in 24-hour urinary excretion rate relative to baseline at Week 12, is calculated by subtracting the urinary excretion rate, \[Week 12\] - \[baseline\], values per patient, then by calculating the median of these changes, per treatment group. Baseline was the average of two, 24-hour urine samples collected before Visit 2 (Week 0).

    Time frame: At baseline and at Week 12.

  4. Pre-dose Plasma Concentration of BI 764198 at Steady-state (Cpre,ss ) at Week 4 and Week 12

    Pre-dose Plasma Concentration of BI 764198 at steady-state (Cpre,ss ) at Week 4 and Week 12 is reported.

    Time frame: At 671.917 hours and at 2015.917 hours after first drug administration.

07

Results

Posted Jan 12, 2026

Participant flow

Randomized, double-blind, parallel group trial to assess the efficacy of 3 doses of BI 764198 (20 mg, 40 mg, and 80 mg) compared to placebo in patients with primary focal segmental glomerulosclerosis (FSGS), or patients with monogenic FSGS as a result of TRPC6 mutations.

Participant flow — Overall Study
MilestoneBI 764198 20 mgBI 764198 40 mgBI 764198 80 mgPlacebo
Started18161716
Treated18151514
Completed18101513
Not completed0623
Withdrew: Adverse event0300
Withdrew: Protocol deviation0200
Withdrew: Withdrawal by subject0001
Withdrew: Not treated0122

Outcome measures

PrimaryAchievement of at Least 25% Reduction in 24-hour Urine Protein Creatinine Ratio (UPCR) Relative to Baseline at Week 12

Predicted probability of patients as a percentage - predicted percentage of patients - achieving at least 25% reduction in 24-hour urine protein creatinine ratio (UPCR) relative to baseline at Week 12 (responders) is reported. Baseline was the average of two 24-hour urine samples collected before Visit 2 (Week 0). Patients who either missed their Week 12, 24-hour UPCR assessment or their Week 12, 24-hour UPCR assessment, occurred later than 5 days after the last dose (Residual Effect Period), were considered as non-responders. The predicted probability of response was calculated using a logistic regression utilizing corticosteroid use at randomization and baseline 24-hr UPCR as covariates and is presented as a percentage.

Time frame:
At baseline and Week 12.
Reported as:
Number · Predicted percentage of patients
Achievement of at Least 25% Reduction in 24-hour Urine Protein Creatinine Ratio (UPCR) Relative to Baseline at Week 12
Predicted percentage of patientsBI 764198 20 mgBI 764198 40 mgBI 764198 80 mgPlacebo
Achievement of at Least 25% Reduction in 24-hour Urine Protein Creatinine Ratio (UPCR) Relative to Baseline at Week 1248.9 (29.2 to 68.6)16.0 (-1.5 to 33.5)38.5 (12.2 to 64.8)11.4 (-2.3 to 25.2)
Statistical analysis
  • BI 764198 20 mg vs Placebo · Odds ratio (or): 10.00 · 95% CI 1.59 to 118.14BI 764198 (comparator) vs. Placebo (reference)
  • BI 764198 40 mg vs Placebo · Odds ratio (or): 1.53 · 95% CI 0.16 to 19.48BI 764198 (comparator) vs. Placebo (reference)
  • BI 764198 80 mg vs Placebo · Odds ratio (or): 5.97 · 95% CI 0.86 to 73.57BI 764198 (comparator) vs. Placebo (reference)
PrimaryRelative Change From Baseline at Week 12 of 24-hour Urine Protein Creatinine Ratio (UPCR)

Relative change from baseline at Week 12 in 24-hour urine protein creatinine ratio (UPCR), is reported. Baseline was the average of two 24-hour urine samples collected before Visit 2 (Week 0). An analysis of covariance (ANCOVA) model was used to estimate the relative change in UPCR from baseline to Week 12 with corticosteroid use at randomization and baseline 24-hr UPCR as covariates.

Time frame:
At baseline and at Week 12.
Reported as:
Least squares mean · Percentage of change in 24-hour UPCR
Relative Change From Baseline at Week 12 of 24-hour Urine Protein Creatinine Ratio (UPCR)
Percentage of change in 24-hour UPCRBI 764198 20 mgBI 764198 40 mgBI 764198 80 mgPlacebo
Relative Change From Baseline at Week 12 of 24-hour Urine Protein Creatinine Ratio (UPCR)-38.44 (-50.41 to -23.60)-2.39 (-24.50 to 26.19)-21.52 (-39.18 to 1.27)2.28 (-20.20 to 31.09)
Statistical analysis
  • BI 764198 20 mg vs Placebo · ANCOVA · p = 0.0024 (Nominal and unadjusted) · Relative difference: -39.82 · 95% CI -56.17 to -17.36Comparison vs Placebo Calculated as (exp(difference of least square means) - 1) \* 100.
  • BI 764198 40 mg vs Placebo · ANCOVA · p = 0.7906 (Nominal and unadjusted) · Relative difference: -4.57 · 95% CI -32.92 to 35.77Comparison vs Placebo Calculated as (exp(difference of least square means) - 1) \* 100.
  • BI 764198 80 mg vs Placebo · ANCOVA · p = 0.1325 (Nominal and unadjusted) · Relative difference: -23.27 · 95% CI -45.83 to 8.70Comparison vs Placebo Calculated as (exp(difference of least square means) - 1) \* 100.
SecondaryChange in 24-hour Urine Protein Creatinine Ratio (UPCR) Relative to Visit 3 at Week 12

Median change in 24-hour urine protein creatinine ratio (UPCR) relative to Visit 3 (Week 1) at Week 12, is calculated by subtracting the 24-hour UPCR, \[Week 12\] - \[Week 1\] values per patient, then by calculating the median of these changes, per treatment group.

Time frame:
At Week 1 and Week 12.
Reported as:
Median · grams/grams
Change in 24-hour Urine Protein Creatinine Ratio (UPCR) Relative to Visit 3 at Week 12
grams/gramsBI 764198 20 mgBI 764198 40 mgBI 764198 80 mgPlacebo
Change in 24-hour Urine Protein Creatinine Ratio (UPCR) Relative to Visit 3 at Week 12-0.035 (-0.812 to 0.669)0.712 (-0.169 to 0.926)-0.4435 (-0.837 to 0.1795)0.106 (-0.496 to 0.497)
SecondaryChange in 24-hour Urine Protein Creatinine Ratio (UPCR) Relative to Baseline at Week 13

Median change in 24-hour urine protein creatinine ratio (UPCR) relative to baseline at Week 13, is calculated by subtracting the 24-hour UPCR, \[Week 13\] - \[baseline\] values per patient,then by calculating the median of these changes, per treatment group. Baseline was the average of two, 24-hour urine samples collected before Visit 2 (Week 0).

Time frame:
At baseline and at Week 13.
Reported as:
Median · grams/grams
Change in 24-hour Urine Protein Creatinine Ratio (UPCR) Relative to Baseline at Week 13
grams/gramsBI 764198 20 mgBI 764198 40 mgBI 764198 80 mgPlacebo
Change in 24-hour Urine Protein Creatinine Ratio (UPCR) Relative to Baseline at Week 13-0.4985 (-0.8080 to 0.5050)-0.151 (-0.6945 to 0.7650)-0.3033 (-0.5875 to 0.3830)0.0795 (-0.4410 to 1.4615)
SecondaryChange in 24-hour Urinary Protein Excretion Relative to Baseline at Week 12

Median change in 24-hour urinary excretion rate relative to baseline at Week 12, is calculated by subtracting the urinary excretion rate, \[Week 12\] - \[baseline\], values per patient, then by calculating the median of these changes, per treatment group. Baseline was the average of two, 24-hour urine samples collected before Visit 2 (Week 0).

Time frame:
At baseline and at Week 12.
Reported as:
Median · grams/day
Change in 24-hour Urinary Protein Excretion Relative to Baseline at Week 12
grams/dayBI 764198 20 mgBI 764198 40 mgBI 764198 80 mgPlacebo
Change in 24-hour Urinary Protein Excretion Relative to Baseline at Week 12-0.5036 (-1.6342 to -0.1112)-0.4056 (-1.0535 to 0.6168)-0.8967 (-1.0484 to -0.0975)0.0809 (-0.8115 to 1.7913)
SecondaryPre-dose Plasma Concentration of BI 764198 at Steady-state (Cpre,ss ) at Week 4 and Week 12

Pre-dose Plasma Concentration of BI 764198 at steady-state (Cpre,ss ) at Week 4 and Week 12 is reported.

Time frame:
At 671.917 hours and at 2015.917 hours after first drug administration.
Reported as:
Geometric mean · nanomole/liter
Pre-dose Plasma Concentration of BI 764198 at Steady-state (Cpre,ss ) at Week 4 and Week 12
nanomole/literBI 764198 20 mgBI 764198 40 mgBI 764198 80 mg
Week 4119 ± 47.2266 ± 64.7683 ± 66.5
Week 12114 ± 85.9328 ± 64.6509 ± 45.7

Adverse events

Collected over All-cause mortality: From first drug-administration until individual end of trial. Up to approximately 16.4 weeks. Adverse event reporting: From first drug administration until stop of treatment + residual effect period (5 days). Up to 14 weeks.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
BI 764198 20 mg0/18 (0%)3/18 (16.7%)14/18 (77.8%)
BI 764198 40 mg0/15 (0%)0/15 (0%)10/15 (66.7%)
BI 764198 80 mg0/15 (0%)1/15 (6.7%)10/15 (66.7%)
Placebo0/14 (0%)1/14 (7.1%)10/14 (71.4%)
Most frequent serious events
Most frequent serious events
EventBI 764198 20 mgBI 764198 40 mgBI 764198 80 mgPlacebo
HypertensionVascular disorders0/180/150/151/14
Blood creatinine increasedInvestigations0/180/151/150/14
OedemaGeneral disorders1/180/150/150/14
OsteonecrosisMusculoskeletal and connective tissue disorders1/180/150/150/14
RhabdomyolysisMusculoskeletal and connective tissue disorders1/180/150/150/14
Most frequent other events
Showing 10 of 76
Most frequent other events
EventBI 764198 20 mgBI 764198 40 mgBI 764198 80 mgPlacebo
FatigueGeneral disorders0/183/150/151/14
HeadacheNervous system disorders3/182/151/152/14
AnaemiaBlood and lymphatic system disorders0/180/150/152/14
NauseaGastrointestinal disorders2/180/150/152/14
ConjunctivitisInfections and infestations0/180/150/152/14
NasopharyngitisInfections and infestations1/180/150/152/14
ArthralgiaMusculoskeletal and connective tissue disorders0/182/150/152/14
Oedema peripheralGeneral disorders0/180/152/151/14
Back painMusculoskeletal and connective tissue disorders0/182/150/150/14
DizzinessNervous system disorders1/180/152/150/14

Baseline characteristics

Treated set: all patients who received at least one dose of trial medication.

Age, Continuous
Age, Continuous(Years)BI 764198 20 mgBI 764198 40 mgBI 764198 80 mgPlaceboTotal
Mean41.2 ± 15.039.8 ± 13.839.8 ± 10.542.2 ± 11.140.7 ± 12.6
Sex: Female, Male
Sex: Female, Male(Participants)BI 764198 20 mgBI 764198 40 mgBI 764198 80 mgPlaceboTotal
Female972725
Male9813737
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)BI 764198 20 mgBI 764198 40 mgBI 764198 80 mgPlaceboTotal
Hispanic or Latino622010
Not Hispanic or Latino1213131452
Unknown or Not Reported00000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)BI 764198 20 mgBI 764198 40 mgBI 764198 80 mgPlaceboTotal
American Indian or Alaska Native00101
Asian332412
Native Hawaiian or Other Pacific Islander10102
Black or African American20114
White11109939
More than one race12104
Unknown or Not Reported00000
Urine Protein-Creatinine Ratio (UPCR) from 24-hour Urine
Urine Protein-Creatinine Ratio (UPCR) from 24-hour Urine(Ratio)BI 764198 20 mgBI 764198 40 mgBI 764198 80 mgPlaceboTotal
Mean4.4865 ± 3.01884.0508 ± 3.00122.6767 ± 2.22094.5166 ± 2.93423.9709 ± 2.8565
08

Study locations

54 sites
  • Nephrology Consultants, LLC
    Huntsville, Alabama 35805, United States
  • University of California San Francisco
    San Francisco, California 94121, United States
  • Valiance Clinical Research-South Gate-67878
    South Gate, California 90280-5219, United States
  • Valiance Clinical Research-Tarzana-68237
    Tarzana, California 91356, United States
  • The Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
    Torrance, California 90502, United States
  • Elixia Fort Lauderdale, LLC
    Fort Lauderdale, Florida 33308, United States
  • South Florida Research Institute
    Lauderdale Lakes, Florida 33313, United States
  • Total Research Group, LLC
    Miami, Florida 33126, United States
  • Emory Children's Center
    Atlanta, Georgia 30322, United States
  • NANI Research, LLC
    Oak Brook, Illinois 60523, United States
  • University of Michigan Health System
    Ann Arbor, Michigan 48109, United States
  • Jacobi Medical Center
    The Bronx, New York 10461, United States
  • The University of North Carolina at Chapel Hill
    Chapel Hill, North Carolina 27599, United States
  • Duke University Medical Center
    Durham, North Carolina 27710, United States
  • Cleveland Clinic
    Cleveland, Ohio 44195, United States
  • The Ohio State University Wexner Medical Center
    Columbus, Ohio 43210, United States
  • University of Pennsylvania
    Philadelphia, Pennsylvania 19104, United States
  • Texas Tech University Health Sciences Center-Amarillo-63885
    Amarillo, Texas 79106, United States
  • Dallas Nephrology Associates Medical Clinic
    DeSoto, Texas 75115-2011, United States
  • Prolato Clinical Research Center-Houston-68087
    Houston, Texas 77054, United States
  • Liverpool Hospital
    Liverpool, New South Wales 2170, Australia
  • Westmead Hospital
    Westmead, New South Wales 2145, Australia
  • Royal Brisbane and Women's Hospital
    Herston, Queensland 4029, Australia
  • Griffith Health
    Southport, Queensland 4125, Australia
  • Sunshine Hospital
    AT Albans, Victoria 3021, Australia
  • UZ Leuven
    Leuven, 3000, Belgium
  • Fu Yang people's Hospital
    Fuyang, 236000, China
  • Guangdong Provincial People's Hospital
    Guangzhou, 510080, China
  • The First Afiliated Hospital, Sun Yet-sen University
    Guangzhou, 510080, China
  • Zhejiang Province People's Hospital
    Hangzhou, 310014, China
  • The First Affiliated Hospital of Nanchang University
    Nanchang, 330006, China
  • The First People's Hospital of Nanning
    Nanning, 530000, China
  • Tongren hospital, Shanghai Jiaotong University School of Medicine
    Shanghai, 200051, China
  • Shanghai Fifth People's Hospital affiliated to Fudan University
    Shanghai, 200240, China
  • HOP Pellegrin
    Bordeaux, 33076, France
  • HOP Bicêtre
    Le Kremlin-Bicêtre, 94270, France
  • HOP Hôtel-Dieu
    Nantes, 44093, France
  • Universitätsklinikum Köln (AöR)
    Cologne, 50937, Germany
  • Medizinische Hochschule Hannover
    Hanover, 30625, Germany
  • Universitätsklinikum Heidelberg
    Heidelberg, 69120, Germany
  • A.O. Policlinico Giovanni XXIII di Bari
    Bari, 70124, Italy
  • Policlinico S. Orsola-Malpighi
    Bologna, 40138, Italy
  • Fondazione Salvatore Maugeri
    Pavia, 27100, Italy
  • New Zealand Clinical Research (ChristChurch)
    Christchurch, 8011, New Zealand
  • Dunedin Hospital
    Dunedin, 9016, New Zealand
  • Hospital Germans Trias i Pujol
    Badalona, 08916, Spain
  • Hospital del Mar
    Barcelona, 08003, Spain
  • Fundació Puigvert
    Barcelona, 08025, Spain
  • Hospital Universitari Vall D Hebron
    Barcelona, 08035, Spain
  • Hospital Clínic de Barcelona
    Barcelona, 08036, Spain
  • Hospital Universitario 12 de Octubre
    Madrid, 28041, Spain
  • St Luke's Hospital
    Bradford, BD5 0NA, United Kingdom
  • Addenbrooke's Hospital
    Cambridge, CB2 0QQ, United Kingdom
  • Salford Royal
    Salford, M6 8HD, United Kingdom
09

References and documents

Publications

  • Trachtman H, Kretzler M, Gesualdo L, Cross N, Workeneh B, Kaufeld J, Meijers B, Ye Z, Chen Q, Derebail VK, Ng MSY, Ji B, Lobmeyer MT, Retlich S, Licariao Rocha FT, Prasad S, Soleymanlou N. TRPC6 inhibition for the treatment of focal segmental glomerulosclerosis: a randomised, placebo-controlled, phase 2 trial of BI 764198. Lancet. 2026 Feb 7;407(10528):587-598. doi: 10.1016/S0140-6736(25)02255-X. Epub 2026 Jan 27. PubMed 41616795 ↗
  • Wooden B, Beenken A, Martinelli E, Saida K, Knob AL, Ke J, Pisani I, Jin G, Lane B, Mitrotti A, Colby E, Lim TY, Guglielmi F, Osborne AJ, Ahram DF, Wang C, Armand F, Zanoni F, Bomback AS, Delsante M, Appel GB, Ferrari MRA, Martino J, Sahdeo S, Breckenridge D, Petrovski S, Paul DS, Hall G, Magistroni R, Murtas C, Feriozzi S, Rampino T, Esposito P, Helmuth ME, Sampson MG, Kretzler M, Kiryluk K, Shril S, Gesualdo L, Maggiore U, Fiaccadori E, Gbadegesin R, Santoriello D, D'Agati VD, Saleem MA, Gharavi AG, Hildebrandt F, Pollak MR, Goldstein DB, Sanna-Cherchi S. Natural History and Clinicopathological Associations of TRPC6-Associated Podocytopathy. J Am Soc Nephrol. 2025 Feb 1;36(2):274-289. doi: 10.1681/ASN.0000000501. Epub 2024 Oct 1. PubMed 39352759 ↗
  • Salemkour Y, Yildiz D, Dionet L, 't Hart DC, Verheijden KAT, Saito R, Mahtal N, Delbet JD, Letavernier E, Rabant M, Karras A, van der Vlag J, Nijenhuis T, Tharaux PL, Lenoir O. Podocyte Injury in Diabetic Kidney Disease in Mouse Models Involves TRPC6-mediated Calpain Activation Impairing Autophagy. J Am Soc Nephrol. 2023 Nov 1;34(11):1823-1842. doi: 10.1681/ASN.0000000000000212. Epub 2023 Sep 6. PubMed 37678257 ↗

Related links

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Once the criteria in section "Time Frame" are fulfilled, researchers can use the following link https://www.mystudywindow.com/msw/datasharing to request access to the clinical study documents regarding this study, and upon a signed "Document Sharing Agreement". Furthermore, researchers can request access to the clinical study data, for this and other listed studies, after the submission of a research proposal and according to the terms outlined in the website.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: After structured results have been posted, all regulatory activities are completed in the US and EU for the product and indication, and after the primary manuscript has been accepted for publication.

Access criteria: For study documents - upon signing of a 'Document Sharing Agreement'. For study data - 1. after the submission and approval of the research proposal (checks will be performed by the sponsor and/or the independent review panel, including checking that the planned analysis does not compete with sponsor's publication plan); 2. and upon signing of a legal agreement.

Data sharing details ↗ · www.mystudywindow.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2022 to primary completion in Jan 2025, 32 months.

Results were first posted in Jan 2026, 1 year after primary completion.

Of 80 industry-sponsored phase 2 interventional studies under Renal Insufficiency, Chronic, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 31. This study's 32 months is above that.

Counting every sponsor, half of 139 studies reached it within 25 months; a quarter within 15 and three quarters within 43.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 27, 2022
First posted
Jan 28, 2022
StartActual
May 3, 2022
Primary completionActual
Jan 3, 2025
CompletionActual
Jan 3, 2025
Results first posted
Jan 12, 2026
Last update
Jan 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 12, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05213624
Responsible party
Sponsor
First posted
Jan 28, 2022
Start date
May 3, 2022
Primary completion
Jan 3, 2025
Completion
Jan 3, 2025
Results posted
Jan 12, 2026
Last update
Jan 12, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: BI-764198

Start the discussion